CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES

BACKGROUND: NTRK gene fusions occur in a range of tumor types, including those with CNS metastases. Larotrectinib, a highly selective FDA- and EMA- approved TRK inhibitor, demonstrated an objective response rate (ORR) of 79% across various cancers (Hong et al. Lancet Oncol. 2020). We report data on...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Patel, Jyoti D, Farago, Anna F, Hong, David S, Lassen, Ulrik N, Leyvraz, Serge, Park, Keunchil, Sohal, Davendra P S, Solomon, Benjamin, Reeves, John A, Dima, Laura, Brega, Nicoletta, Drilon, Alexander
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2020
Предметы:
Clinical Trials: Non-Immunologic
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650347/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.171
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы